Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity (2018 - 2026)

Mirum Pharmaceuticals has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $890.9 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 29.07% year-over-year to $890.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (up 20.64% YoY), and the FY2025 full-year result was $842.8 million, up 25.65% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $890.9 million, up from $842.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $890.9 million in Q1 2026, with the low at $278.1 million in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $585.5 million, with a median of $652.0 million recorded in 2024.
• Peak annual rise in Liabilities and Shareholders Equity reached 95.47% in 2024, while the deepest fall reached 2.65% in 2024.
• Tracing MIRM's Liabilities and Shareholders Equity over 5 years: stood at $352.9 million in 2022, then jumped by 83.23% to $646.6 million in 2023, then climbed by 3.73% to $670.8 million in 2024, then rose by 25.65% to $842.8 million in 2025, then climbed by 5.71% to $890.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $890.9 million (Q1 2026), $842.8 million (Q4 2025), and $785.1 million (Q3 2025), per Business Quant data.

Peer Comparison